US 11850225
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted A61KA61K31/197
Quick answer
US patent 11850225 (Baclofen formulations and methods of minimizing patient exposure to metabolite variations) held by AMNEAL PHARMACEUTICALS LLC expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/197